Provectus Pharmaceuticals Inc. CEO To Speak At Melanoma Research Foundation Board Meeting

KNOXVILLE, Tenn., Oct. 3 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals announced today that Provectus' CEO Craig Dees, Ph.D., is scheduled to speak before the Melanoma Research Foundation at its annual board meeting in Newark, New Jersey on Friday, October 6, 2006. In his presentation, Dees is expected to detail the promise of the Company's leading anti-cancer agent, PV-10, its ability to ablate metastatic melanoma tumors, and the recent clinical evidence backing up that claim.

Derived from the Rose Bengal dye historically used in healthcare imaging, Provectus' proprietary drug PV-10 (Provecta(TM)), specifically focuses its activity on tumor tissue and destroys it while leaving healthy tissue intact and unharmed, making it safer and potentially more effective than conventional therapies, such as chemotherapy and radiation. In clinical trials, PV-10 has also induced the destruction of multiple untreated melanomas, called the "bystander effect," after treatment of melanoma tumors elsewhere in the body. Since one of the greatest challenges in treating melanoma is the tendency for the cancer to metastasize to other places within the body, the bystander effect gives hope that patients treated with PV-10 will experience a systemic benefit.

"The Melanoma Research Foundation continues to be a tireless advocate for raising the awareness level of malignant melanoma, and we believe that its unceasing support to the scientific community will lead to more effective treatments like that represented by PV-10," said Dees.

About Melanoma Research Foundation:

The Melanoma Research Foundation (MRF) was founded 10 years ago and has become the leading research foundation for melanoma. The Foundation has worked closely with the research and medical community to encourage dialog to increase chances of cure through its research congresses; participated in National Cancer Institute initiatives; organized the first steps of a melanoma coalition for advocacy; and hosts a very active interactive website for patients and caregivers. Its three part mission, supporting basic and translational research, education of patients and caregivers, and advocating for the melanoma community is funded primarily through community fundraisers across the United States organized and managed by MRF volunteers. Other primary sources include memorial donations, individual gifts, and unrestricted grants from pharmaceuticals.

About Provectus Pharmaceuticals, Inc.:

Provectus Pharmaceuticals, Inc. is a pioneering pharmaceutical company actively engaged in the design, development, and marketing of pharmaceutical technologies for the treatment of breast cancer, liver cancer, and metastatic melanoma. In addition, Provectus is preparing to begin Phase 2 clinical studies for the Company's topical agent Xantryl(TM), a treatment for psoriasis.

The Company's offices and laboratory are located at 7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931; telephone: 865-769-4011. For more

information, contact the Company at info@pvct.com or visit the corporate Web site: http://www.pvct.com.

This release and others statements issued or made from time to time by the company or its representatives contain comments that may constitute forward- looking statements. Those include statements regarding the intent, belief or current expectations of the company and members of its management teams, as well as the assumptions on which the statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward- looking statements.

Provectus Pharmaceuticals, Inc.

CONTACT: Peter Culpepper of Provectus Pharmaceuticals, Inc.,+1-865-769-4011, or culpepper@pvct.com; or investors, Matt Clawson of Allen& Caron Inc., +1-949-474-4300, or matt@allencaron.com, for ProvectusPharmaceuticals, Inc.

Back to news